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Abstract
Background: Patient safety research has focused largely on hospital settings despite the fact that in many countries,
the majority of patient contacts are in primary care. The knowledge base about patient safety in primary care is
developing but sparse and diagnostic error is a relatively understudied and an unmeasured area of patient safety.
Diagnostic error rates vary according to how ‘error’ is defined but one suggested hallmark is clear evidence of ‘missed
opportunity’ (MDOs) makes a correct or timely diagnosis to prevent them. While there is no agreed definition or
method of measuring MDOs, retrospective manual chart or patient record reviews are a ‘gold standard’. This study
protocol aims to (1) determine the incidence of MDOs in English general practice, (2) identify the confounding and
contributing factors that lead to MDOs and (3) determine the (potential) impact of the detected MDOs on patients.
Methods/Design: We plan to conduct a two-phase retrospective review of electronic health records in the Greater
Manchester (GM) area of the UK. In the first phase, clinician reviewers will calibrate their performance in identifying and
assessing MDOs against a gold standard ‘primary reviewer’ through the use of ‘double’ reviews of records. The findings
will enable a preliminary estimate of the incidence of MDOs in general practice, which will be used to calculate the
number of records to be reviewed in the second phase in order to estimate the true incidence of MDO in general
practice. A sample of 15 general practices is required for phase 1 and up to 35 practices for phase 2. In each practice,
the sample will consist of 100 patients aged ≥18 years on 1 April 2013 who have attended a face-to-face ‘index
consultation’ between 1 April 2013 and 31 March 2015. The index consultation will be selected randomly from each
unique patient record, occurring between 1 July 2013 and 30 June 2014.
Discussion: There are no reliable estimates of safety problems related to diagnosis in English general practice. This
study will lay the foundation for safety improvements in this area by providing a more reliable estimate of MDOs, their
impact and their contributory factors.
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Background
Patient safety has received considerable global attention
since the publication of the landmark report ‘To Err is
Human’ in 1999 [1]. This attention has however been fo-
cused largely toward hospital settings leading to the iden-
tification of a so called ‘lost decade’ with respect to
settings such as primary care [2]. This is despite the fact
that in many countries, including the United Kingdom
(UK), the majority of patient contacts are with health care
providers in primary care. The knowledge base about pa-
tient safety in this setting is still sparse [3] and some may
still perceive primary care as a low-risk environment.
However, a recent review estimated that there may be a
patient safety incident in approximately 2 % of all family
practice consultations [4]. Moreover, the sheer volume of
patient contacts (approximately 340 million consultations
per year in the UK [5]) multiplies opportunities for errors.
A recent systematic review of tools that can be used by
family practitioners as part of a patient safety toolkit found
that tools for diagnostic error accounts for <1 % of total
literature [6]. Diagnostic error remains relatively under-
studied and unmeasured area of patient safety [7].
Diagnostic error
Data about the incidence, types and causes of errors en-
countered in primary care are scant and there are no large-
scale epidemiological studies in the UK to reliably quantify
error and harm rates in this setting. However, among the
different types of errors, medication-related errors and
diagnostic errors (DEs) are the most common in primary
care [8, 9]. Despite their potential and actual significant im-
pact, DE have received less attention relative to other types
of error even though there is evidence to suggest that DEs
are more common in primary than in secondary care set-
tings [9–11]. DE-associated harm has been estimated at
0.1 % of primary care diagnoses, but the overall DE rate
may be as high as 15 % [12]. Recent work in the United
States (US) combining data from three large observational
studies estimated that 5 % of US adults will experience a
DE every year in the outpatient setting, but comparative
data from the UK is lacking. DE rates vary according to dif-
ferent diseases and their myriad clinical presentations, with
atypical and non-specific presentations substantially in-
creasing the risk of DE. However, no single disease ac-
counts for more than 5 % of malpractice claims [13].
Defining diagnostic error
DE rates are likely to vary substantially according to the
criteria used to define ‘error’. A central issue in the reli-
able measurement of DE is therefore how it is defined.
Some studies define diagnostic error as any diagnosis
that is (i) wrong, e.g. another diagnosis was made before
the correct one; (ii) delayed, e.g. insufficient information
was available to make an earlier diagnosis; or (iii) missed,
e.g. no diagnosis was ever made. The decision as to
whether a diagnostic error occurred or not is judged from
a subsequent assessment of more definitive information,
regardless of whether an error in the diagnostic process
occurred [14, 15]. To address this potential limitation, it
has recently been argued that the definition of a diagnostic
error should include the requisite of clear evidence of
‘missed opportunities’ to prevent them [16]. There are
three specific aspects to a ‘missed opportunity’:
1. Case analysis reveals evidence of a missed
opportunity to make a correct or timely diagnosis.
The concept of a missed opportunity implies that
something different could have been done to make
the correct diagnosis earlier. The missed opportunity
may result from cognitive and/or system factors or
may be attributable to more obvious factors, such as
lapses in accountability or clear evidence of liability
or negligence.
2. A missed opportunity is framed within the context
of an ‘evolving’ diagnostic process. The
determination of error depends on the temporal or
sequential context of events. Evidence of omission
(failure to do the right thing) or commission (doing
something wrong) exists at the particular point in
time at which the ‘error’ occurred.
3. The opportunity could be missed by the provider,
care team, system, and/or patient. A preventable
error or delay in diagnosis may occur due to factors
outside the clinician’s immediate control or when a
clinician’s performance is not contributory [16].
In this study, we define and conceptualise diagnostic er-
rors therefore as ‘missed diagnostic opportunities’ (MDOs).
Aetiology and impact of MDOs
Research suggests that the aetiology of the vast majority
of MDOs is multi-factorial and arises via a complex
interplay of system and cognitive contributory factors
[14]. One potentially useful classification identifies five
interactive process dimensions: (i) the patient-provider
encounter (history, exam, ordering tests/referrals based
on assessment); (ii) performance and interpretation of
diagnostic tests; (iii) follow-up and tracking of diagnostic
information over time; (iv) subspecialty and referral-
specific issues; and (v) patient-related factors [17]. Re-
gardless of their origins, diagnostic errors can have
important consequences [18, 19]:
 Patients may suffer preventable harm, for example
through conditions which remain untreated or by
receiving inappropriate and unnecessary treatment;
 Doctors may be subject to malpractice claims
(diagnostic error accounts for approximately two-
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thirds of malpractice claims against general practi-
tioners (GPs) in the UK); and
 Additional financial costs are incurred by health
care systems.
Rationale for studying MDOs
The lack of progress in understanding and determining
MDOs and in particular MDOs in primary care may be
attributed to several factors. The diagnostic process
often spans multiple health care settings and involves
different professional staff groups, which in turn intro-
duces myriad challenges, such as co-ordinating care and
managing the timely and secure communication of pa-
tient information. Furthermore, diagnoses are made dur-
ing time-pressured consultations within primary care
settings, where providers are often remain unaware of
ultimate patient outcomes [17]. As a result, it is hard to
detect MDOs, ascertain their underlying causes and, ul-
timately, very difficult to prevent them [17]. Consequently,
measuring MDOs and calculating a reliable ‘error rate’ is
challenging. To date, the incidence of MDOs has been es-
timated using at least eight different methods [11]. Each
method has its associated strengths and weaknesses, but
retrospective manual chart or patient record reviews are
considered the ‘gold standard’ [20]. Although laborious,
the method allows for the overarching diagnostic process
to be traced and account diagnoses that evolves over time.
Identifying, measuring and understanding MDOs in
primary care is the first step in developing policies and
interventions to reduce harm and improve patient safety
in this area. At present, we have no reliable estimates of
diagnostic error in English general practice with which
to formulate any such policies or interventions, hence
the need for this work.
Aims and objectives
The study has three specific aims:
 To determine the incidence of MDOs in English
general practice;
 To identify the confounding and contributing
factors that lead to MDOs; and
 To determine the impact or potential impact of the
detected MDOs on patients
The secondary objectives of the study are:
 To test for significant associations between MDO
rates and specific patient, index consultation,
practice and diagnostician variables.
 To compare the MDO rates of the participating
practices and different professional groups.
 To describe the types of diagnoses clinicians made




The study design is a retrospective review of electronic
medical records that will be undertaken in two consecu-
tive phases. In the first phase, clinician reviewers will
gain experience and confidence in the review method
and at the same time calibrate their performance in
identifying and assessing MDOs against a gold standard
‘primary reviewer’ through the use of ‘double’ reviews of
records. Thus, a primary goal of this phase is to maxi-
mise consistency of ratings across reviewers. The review
findings from phase 1 will then be used to calculate a
preliminary estimate of the incidence of MDOs in gen-
eral practice. This preliminary rate will be used to calcu-
late the number of records to be reviewed in the second
phase in order to estimate the true incidence of MDO in
general practice to a specified degree of precision and
reliability. In other words, the MDO rate from phase 1
will ensure that no more than the required number of
records is reviewed during phase 2. This is an essential
requirement of the study to ensure that the available re-
sources are used efficiently.
Setting
The study will be conducted in the Greater Manchester
(GM) area. More specifically, the electronic patient records
of general practices in the GM Clinical Commissioning
Groups (CCGs) will be considered for potential inclusion.
However, practice staff and patients will not directly be in-
volved in any aspect of the study.
Samples
i. The sampling strategy will involve random selection
of sets of electronic health records from a stratified
sample of general practices.
General practices
A sample of 15 general practices is required for phase 1 of
the review process. An additional sample of 35 practices
may be required for phase 2. However, this is an estimate
that will be revised as described in ‘Calculation of sample
size’ section below.
Purposeful sampling will be used to select a sample of
practices stratified by size and neighbourhood deprivation.
Practice size will be based on the number of registered
patients and coded as ‘large’, ‘medium’ or ‘small’. Neigh-
bourhood deprivation will be based on the national quin-
tiles of the English Index of Multiple Deprivation (IMD)
for 2010 [21], based on the postcode of the general prac-
tice. In addition, a pragmatic requirement for suitable
practices will be availability of space for the administrator
and clinician reviewers.
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ii. Electronic health records
Electronic health records for 100 unique patients that
meet the following four inclusion criteria will be randomly
sampled from each participating practice: (1) age ≥18 years
old on the 1 April 2013; (2) registered continuously with
the same practice from 1 April 2013 to 31 March 2015
(thus excluding records of temporary residents); (3) avail-
ability of the complete medical record for review; and (4)
must have attended a face-to-face ‘index consultation’ dur-
ing this period.
Each patient’s index consultation represents the ‘anchor’
of the review process and marks the reviewers’ starting
point for that patient. A single index consultation will be
randomly selected from each unique patient record, oc-
curring within the 12-month period commencing on 1
July 2013 and ending on 30 June 2014. Across the patient
sample within each practice, the index consultation dates
will be spread over the course of the defined 12-month
period to account for potential seasonal effects on reasons
for consulting and hence MDOs. This will be done by
assigning four week-long sampling ‘windows’ to the prac-
tice and randomly selecting 25 index consultations from
all patient consultations within each window. The first
sampling window will be randomly chosen from the first
13 weeks of the period and each subsequent window will
be 13 weeks later.
Reviewers
Five GPs will be recruited and trained as clinician re-
viewers and will meet the following inclusion criteria: (1)
currently working as a GP or has worked as a GP in the
last 12 months; and (2) a minimum of 5 years’ experi-
ence as a GP. Based on previous experience and know-
ledge of safe practice, one of the five GPs will be
designated the ‘primary reviewer’ and will undergo add-
itional training and calibration with clinical members of
the project research team group. The primary reviewer
will then act as the gold standard against which the per-
formance of the four remaining GPs in identifying and
evaluating MDOs will be calibrated.
Calculation of sample size
Phase 1 sample The primary objectives of phase 1 are
to calibrate the reviewers with the primary reviewer and
to collect sufficient data to reliably estimate the sample
required for phase 2. For these purposes, we have deter-
mined that a phase 1 sample of 15 practices and 100 re-
cords at each will be required. For calibration, the study
uses overall sensitivity and specificity of the reviewers of
75 % or better as acceptable and 60 % or less as fully un-
acceptable, assessed using the latter 50 % of records (see
‘Data analysis’ section below). For an MDO rate of 5 %
or higher and true sensitivity and specificity of 75 % or
better, this sample will produce observed sensitivity and
specificity with more than 99 % likelihood of being
greater than 60 %: that is, with a less than 1 % chance
that truly acceptable calibration will be mistaken as un-
acceptable, and vice versa. This calculation (and those
below) also assumes that 20 % of records will contain no
new diagnosis and therefore contribute no usable data
(based on clinical experience).
The sample will also yield sufficiently precise estimates of
both the overall MDO rate and of the degree of clustering
of MDOs within practices (measured by the intra-cluster
correlation coefficient (ICC)) to estimate the required
sample at phase 2. Assuming a fairly high ICC of 0.05
(which for an overall MDO rate of 5 % implies that 95 %
of individual practices have rates between 0 % and 15 %),
this sample will yield an MDO rate with a 95 % confidence
interval of 2.3–7.7 % when the true rate is 5 %; and 6.2–
13.8 % when the true rate is 10 %.
Phase 2 sample The number of electronic patient re-
cords to be sampled and reviewed at phase 2 will depend
upon the estimates of the MDO rate and the ICC obtained
from phase 1. In addition, to allow estimation of the rela-
tive rates of different forms of MDO, we aim to pick up a
minimum of 100 MDOs in total across phase 1 and phase
2 combined (to give an error of +/−10 % on an MDO ac-
counting for 50 % of all MDOs; +/−6 % on an MDO ac-
counting for 10 %). As a pre-check that sample sizes will
be sufficient for this purpose, we have made estimates for
three true MDO rate scenarios: 1, 5 and 10 % (at an ICC
of 0.05). The results are shown in Table 1.
If the overall MDO rate from phase 1 is 5 % (Table 1,
scenario 2), we will need to review a total of 5000 records,
comprised of samples of 100 records selected from each
of 50 general practices (15 at phase 1 plus 35 at phase 2).
We calculate that this sample will yield approximately 200
MDOs and produce an estimate of the true MDO rate
with error limits of at most 1.5 % (i.e. a 95 % confidence











95 % CI on the
estimated MDO rate
1 1 50 250 12500 100 0.4-1.6
2 5 50 100 5000 200 3.5-6.5
3 10 40 100 4000 320 7.7-12.3
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interval of 3.5–6.5 %). If the MDO rate at phase 1 is close
to 1 %, we would instead need to review 250 records at
each of 50 practices (12,500 in total) to obtain 100 MDOs
(Table 1, scenario 1). To achieve this may be outside of
the resources of the study hence if this is the case, we will
revisit the aims of the main study.
Recruitment
Recruitment will commence as soon as we have obtained
NHS Research Ethics Committee, Confidentiality Advis-
ory Group and Research & Development (R&D) approvals
for the study and will continue until we have recruited the
requisite number of general practices as described in the
‘Samples’ section. We aim to recruit CCGs, general prac-
tices, an administrator and clinician reviewers.
CCGs The recruitment process will begin by contacting
the GM CCGs and meeting with their leaders in order to
seek their support and approval for participation in this
study. Each GM CCGs has many general practices with
diverse geographical spread and wide-ranging socio-
economic conditions and all of them will be considered
once we have obtained senior leadership support.
General practices We will send practices an introductory
letter (Additional file 1) and further information about the
study in an information sheet (Additional file 2) by post as
well as a slip to allow practices to express an interest in
participating, with pre-paid envelopes to return the con-
sent forms (Additional file 3). The information sheet will
outline the aims of the study, the method, potential risks
and benefits of participating as well as the service support
costs we can offer to practices. The recruitment letter will
be signed by the Greater Manchester Primary Care Patient
Safety Translational Research Centre (PSTRC) Principal
Investigator (PI) and Medical Director of the relevant
CCG. Two further reminders will be sent to those prac-
tices that do not respond at fortnightly intervals. Partici-
pating practices will be reimbursed £1000 for taking part.
Administrator
The administrator will be recruited from the Greater
Manchester PSTRC and receive further training relevant
to the study tasks. The main task of the administrator
will be to compile a list of index consultations (one per
record) in each participating practice as the first step in
the review process.
Clinician reviewers
One reviewer will be recruited from each of the three par-
ticipating CCGs if feasible. Two additional reviewers will
be recruited, one as the ‘primary reviewer’ and the other as
a ‘floater’ to allow for holidays and unforeseen eventualities
in the lives of the other reviewers. The reviewers will be re-
munerated for their time in accordance with locum rates.
Data collection
Data preparation
The administrator will visit each practice to create a list of
‘index consultations’ (one per patient record) and to
complete the ‘patient demographic’ section on the data ex-
traction form (DEF: Additional file 4) and separate ‘practi-
tioner’ and ‘practice demographics’ sections on the DEF
that was specifically designed for this study (Additional file
5). All relevant consultations for the 12-month period (1
July 2013 to 30 June 2014) will initially be identified by the
administrator. From these, the required number (n = 100)
of unique and eligible index consultations will be selected
by using the Random Integer Set Generator.1
Period of review in each record
A minimum of 12 months will be reviewed in each rec-
ord. More specifically, a period of 3 months before and
9 months after the selected index consultation in each
record will be reviewed (Fig. 1). This timeframe is in-
formed by the research team’s previous experience and
is also similar to comparable studies of MDOs [22].
However, we acknowledge that some MDOs may only
become apparent after a longer duration of time. Re-
viewers may therefore, at their own discretion, choose to
extend the review period.
Fig. 1 The minimum period of review in each record (12 months)
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The four-step review process
The vast majority of data will be collected by the adminis-
trator and clinician reviewers using a structured, four-step
review process and a DEF (Additional file 4) specifically
designed for this study. The four consecutive steps
are to:
1. Gather information about the index consultation;
2. Record the diagnosis or diagnoses that were made
during the index consultation;
3. Gather information relating to the diagnosis or
diagnoses;
4. Rate and describe the characteristics of the diagnosis
or diagnoses and any MDOs
Further details about the four steps are available as an
Additional file (Additional file 6) and the practical appli-
cation of the steps are described in a coding manual
(Additional file 6). Some of the main points are dis-
cussed below.
Step 1: Gather information about the index consultation
This part of the data collection will be performed by the
administrator while steps 2–4 will be performed by the
clinician reviewers. The following information will be ex-
tracted by the administrator from the index consultation
in each record:
 The date, place (either home visit or at the practice)
and time of day of the selected index consultation
(08:00–11:59, 12:00–13:59; 14:00–18.30; or out-of-
hours);
 The age of the patient on the day of the index
consultation;
 The patient’s gender;
The following information will be extracted by the ad-
ministrator from each record on the day the search is
conducted:
 The number of repeat medication items
prescribed;
 The type and number of documented morbidities
Step 2: Recording the diagnosis or diagnoses that were
made during the index consultation
During this part of the data collection, the clinician re-
viewers collect information on the diagnosis or diagnoses
that were made during the index consultation. If there
were no diagnosis made, the review for that specific rec-
ord is effectively over, and the reviewer continues with the
next record.
Step 3: Gather information relating to the diagnosis or
diagnoses
Reviewers will systematically gather information about the
index consultation diagnosis or diagnoses in order to
make professional judgments in step 4 about (i) the accur-
acy of each diagnosis and (ii) whether there had been
missed diagnostic opportunities. The systematic approach
involves searching for the presence of seven predefined
‘triggers’ or prompts in each record and considering eight
questions about potential MDOs (Additional file 6), based
on the work in the US by co-author Singh [16].
Step 4: Rate and describe the characteristics of the
diagnosis or diagnoses and any MDOs
Reviewers will use their clinical experience and the in-
formation they gathered in step 3 to rate and record the
following on the DEF for each record:
 The accuracy of each diagnosis;
 Whether there were MDOs, and their confidence in
this finding;
 The potential impact of MDOs on patients;
 Factors that may have contributed to the MDOs;
 A description of the MDO;
 Any other relevant comments, reflections or
feedback
Feasibility
Based on the steering group’s experience, we estimate that
clinicians can review approximately 25 electronic medical
records and complete a DEF for each in a 4-hour session.
Inter-rater agreement
We aim to achieve a high-level of inter-rater agreement be-
tween clinician reviewers by providing formal training, on-
going ‘expert’ and peer support and double coding and
calibration during phase 1 of the review process, plus some
monitoring to ensure continued calibration during phase 2.
Initial training and ongoing support
GP reviewers will receive 2 days of training, consisting of
face-to-face presentations, opportunity to practice new
skills with case studies, feedback on performance and par-
ticipation in an open-forum discussion. In addition, they
will be provided with a range of educational materials, in-
cluding a coding manual (Additional file 6). The steering
group will be available throughout the study period to
provide support as required.
Phase 1 calibration and double coding
During phase 1, the primary reviewer will review every
record in the sample. Each of the three other reviewers
(reviewers 2–4) will be paired with the primary reviewer
in 5 of the 15 practices (Table 2). A fifth reviewer has also
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been trained in case one or the main reviewers is unable
to continue. The fifth reviewer will be calibrated to the
gold standard across ten practices (rather than five) to en-
sure they could stand in for the primary reviewer them-
selves if the need arises. The order of the reviewers will be
varied from practice to practice so that the initial reviewer
is not always the same. The reviewers will complete the
DEF for each record independently of each other before
comparing their findings and ratings. Any differences will
be resolved through discussion to reach consensus.
Phase 2 reviews
Assuming that an adequate level of calibration is achieved
in phase 1, the records for each practice participating in
phase 2 will be reviewed by one of the four reviewers only.
However, the primary reviewer will double-check ten re-
cords from each of the other reviewers at every third prac-
tice they rate (making around an extra 150 reviews in all).
Data analysis
For analysis purposes, the data from phases 1 and 2 will
be pooled together, with the data for each phase 1 practice
being the agreed final ratings between the two reviewers.
Descriptive analysis
Simple descriptive statistics, including means, standard
deviations, medians and inter-quartile ranges, will be
used to characterise the overall MDO rate and individual
practice and subgroup rates, e.g. professional group and
month of year. The precision of the MDO rate estimates
from each analysis will be expressed in terms of the con-
fidence interval around the rate. The overall rate of
MDOs will be calculated by aggregating all practice data
from phases 1 and 2. In addition, we will compare the
distribution of the sample of practices in terms of key
practice variables (e.g. list size, IMD) to all practices in
GM and in England and derive weights from this in
order to compute weighted estimates of the mean rates
for these larger geographical areas.
Analysis of free-text data will be undertaken by the re-
viewers, research team and steering group. We will produce
an output similar to Singh [23] to outline the symptoms
and primary types of missed diagnostic opportunities.
Symptoms and diagnoses will be coded and summarised
using descriptive statistics.
Predictive factors
We will use multilevel logistic regression (records within
clinicians within practices) to investigate a wide range of
variables potentially associated with MDOs (Table 3).
The analysis will be conducted according to an a priori
analysis plan that fully specifies the outcome and ex-
planatory factors, other covariates, treatment of missing
values and methods of analysis.
Reviewer agreement
Inter-rater agreement will be assessed through calculation
of specificity and sensitivity for each of the four secondary
reviewers relative to the primary reviewer using the phase 1
data. Agreement will be based on ratings for the latter 50 %
of records in each case; with the first 50 % being regarded
as principally a training set. Sensitivity and specificity rates
of ≥75 % will be considered as acceptable, ≤60 % as requir-
ing further calibration and 60–75 % as requiring input from
Table 2 Reviewer pairs in phase 1 of the review process.
Reviewer Practice
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
1a X X X X X X X X X X X X X X X
2 X X X X X
3 X X X X X
4 X X X X X
5 X X X X X X X X X X
aPrimary reviewer
Table 3 Variables potentially associated with MDOs
Main variable Specific aspects to consider for analysis
Patient Age
Gender
Number of chronic conditions





Location of consultation (at home or in practice)
Diagnostician Professional role (as recorded on Additional file 6)
Gender (as recorded on Additional file 6)
Age (as recorded on Additional file 6)
Country in which professional qualifications
were obtained (as recorded on the General
Medical Council [GMC] register)
Number of years of clinical experience
(as recorded on the GMC register)
General practices Size of practice, based on the number of
registered patients (recorded on Additional file 6)
Type of contract type (Personal Medical Services
[PMS] v General Medical Services [GMS]) (recorded
on Additional file 5: clinician and demographic form)
Area of deprivation (as recorded by the English
Indices of Multiple Deprivation (IMD)
https://www.gov.uk/government/statistics/
english-indices-of-deprivation-2010),
Quality and outcomes framework (QOF)
performance (as recorded by the Health and
Social Care Information Centre:
http://www.hscic.gov.uk/catalogue/PUB12262);
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the research team steering group to decide whether further
calibration is required or not.
Study duration and timeline
The study started with literature review, planning, consult-
ation, preparation and finalising this protocol. We have full
ethical and R&D approvals, and data collection will begin
soon. Data collection in all of the participating practices is
estimated to last a maximum of 12–16 months. The study
endpoint, including analyses and write-up is estimated to
be December 2016 to March 2017.
Ethical and research and development approvals
Ethical approval for the study was obtained from NRES
Committee North West-Lancaster on 23/03/15 (refer-
ence: 14/NW/1491). Approval was also obtained from
the Confidential Advisory Group on 9/03/15 (reference:
14/CAG/1041).
We do not plan to seek individual patient consent for ac-
cess to patient records. This is because the records will be
reviewed by GPs who are currently, or have been within
the last 12 months, employed by the NHS and no patient
identifiable information will be collected or used in any
part of the analysis or reporting of the study findings. In
addition, GPs regularly perform and are expected to per-
form clinical audit as part of their normal work activities.
Discussion
There are no reliable estimates of the incidence of
MDOs in English general practice. Current estimates are
based often on anecdotes, personal experience and a
number of small studies conducted, for example in the
UK (4,8) There are many challenges in measuring diag-
nostic error and MDOs and in developing and using
good measurement instruments; and the ability to re-
duce diagnostic errors hinges on the ability to overcome
measurement-related challenges [7, 24]. Aside from the
lack of epidemiological accuracy, the inability to date to
measure MDOs impedes the formulation of policies or
interventions to address and reduce MDOs. Hence, this
project is taking multiple precautions to ensure reliabil-
ity and accuracy such as training and ongoing monitor-
ing of reviewers to maximise calibration through a
process of double coding, and setting sample sizes ac-
cording to designated degrees of precision. As a result of
this project, future research will have an available and a
more reliable estimate of MDOs as a prerequisite to im-
provement, which the American Medical Association
(AMA) has highlighted as a priority because the literature
on improving safety in primary care is still evolving [2].
While a forthcoming Institute of Medicine report on diag-
nostic error is bound to shed more light on the import-
ance of this area, an embedded implementation strategy
will be needed to drive improvement or a quality cycle to
alter strategies and measure for change [25]. Some have
advocated the need for outcome measures in patient
safety [26], and a methodology to estimate more reliable
levels of MDOs will be a key step in that direction. Mea-
sureable outcomes must be used alongside training, policy,
culture and feedback of outcomes data in line with other
established models of patient safety [27, 28]. In addition to
providing foundational data on diagnostic errors, findings
from this study could be used also for educational pur-
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